A world without malaria.

Clinical development of a new combination of anti-malarial therapy, Ganaplacide/Lumefantrine for malaria control and elimination.

The objectives of WANECAM 2 are:

• To accelerate the clinical development and, if successful, registration of this new innovative anti-malarial drug candidate Ganaplacide combined with a new formulation of lumefantrine (solid dispersion formulation, LUM-SDF) and evaluate its safety, tolerability and efficacy in the treatment of uncomplicated falciparum malaria in children aged 6 months and above, and adults in West and Central Africa;
• To further develop capacities in clinical research, laboratory skills and infrastructure in sub-Saharan Africa by significantly enhancing the clinical trial expertise of a new clinical research team in Niger, improving targeted capacities and other infrastructure in all teams involved as well as training young African and European scientists;
• To strengthen and expand the existing previously EDCTP funded West African network for clinical trials of antimalarial drugs (WANECAM 2) through intra-European, European-African and intra-African collaborative activities.